The Medicines Intelligence Data Platform: A population-based data resource from New South Wales, Australia

Helga Zoega,Michael O Falster,Malcolm B Gillies,Melisa Litchfield,Ximena Camacho,Claudia Bruno,Benjamin Daniels,Natasha Donnolley,Alys Havard,Andrea L Schaffer,Georgina Chambers,Louisa Degenhardt,Timothy Dobbins,Natasa Gisev,Rebecca Ivers,Louisa Jorm,Bette Liu,Claire M Vajdic,Sallie-Anne Pearson
DOI: https://doi.org/10.1101/2024.04.29.24306520
2024-04-30
Abstract:The is an anonymised linked data resource designed to generate real-world evidence on prescribed medicine use, safety, costs and cost-effectiveness in Australia. The platform comprises Medicare-eligible people who are ≥18 years and residing in New South Wales (NSW), Australia, any time during 2005-2020, with linked data on dispensed prescription medicines (Pharmaceutical Benefits Scheme), health service use (Medicare Benefits Schedule), emergency department visits (NSW Emergency Department Data Collection), hospitalisations (NSW Admitted Patient Data Collection), cancer notifications (NSW Cancer Registry), fact and cause of death (National Death Index). Data are currently available to 2022, with approval to update the cohort and data collections annually. The platform includes 7.4 million unique people across all years, covering 36.9% of the Australian adult population; the overall population increased from 4.8M in 2005 to 6.0M in 2020. As of 1 January 2019 (the last pre-pandemic year), the cohort had a mean age of 48.7 years (51.1% female), with most people (4.4M, 74.7%) residing in a major city. In 2019, 4.4M people (73.3%) were dispensed a medicine, 1.2M (20.5%) were hospitalised, 5.3M (89.4%) had a GP or specialist appointment, and 54 003 people died. Anti-infectives were the most prevalent medicines dispensed to the cohort in 2019 (43.1%), followed by nervous system (32.2%) and cardiovascular system medicines (30.2%). The creates opportunities for national and international research collaborations and enables us to address contemporary clinically- and policy-relevant research questions about quality use of medicines and health outcomes in Australia and globally.
Public and Global Health
What problem does this paper attempt to address?